Related Experiment Video

Updated: Jan 13, 2026

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
09:54

Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models

Published on: December 3, 2019

10.5K

Incidence and Clinical Significance of Recompensation After HCV Cure

Georg Semmler1, Sabela Lens2, Álvaro Hidalgo3

  • 1Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|May 16, 2025
PubMed

Insights

Achieving recompensation after hepatitis C virus (HCV) cure significantly reduces liver-related death and portal vein thrombosis risk. However, hepatocellular carcinoma incidence remains high, indicating ongoing risks even after HCV eradication.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Medicine

Background:

  • Baveno VII criteria for cirrhosis recompensation require validation in hepatitis C virus (HCV) cured patients.
  • Prognostic significance of recompensation in advanced chronic liver disease (ACLD) post-HCV cure is understudied.

Purpose of the Study:

  • To investigate the incidence and impact of recompensation after HCV cure.
  • To identify predictors of recompensation in patients with ACLD.
  • To assess the association between recompensation and clinical outcomes like HCC, PVT, and liver-related death.

Main Methods:

  • Retrospective analysis of 2570 patients with ACLD from 10 European centers.
  • Inclusion of patients achieving sustained virologic response to direct-acting antivirals (DAAs).
  • Investigation of recompensation's link to hepatocellular carcinoma (HCC), portal vein thrombosis (PVT), and liver-related death.

Main Results:

  • Recompensation was achieved by 36.6% of patients during a median 8.4-year follow-up.
  • Lower albumin and diabetes were negatively associated with recompensation.
  • Recompensation significantly reduced liver-related death (4.2 vs 8.8 per 100 patient-years) and PVT (2.7 vs 5.4), but HCC incidence remained high (3.9 vs 5.5).

Conclusions:

  • HCV cure-induced recompensation is linked to decreased mortality and PVT risks.
  • Recompensation does not reduce hepatocellular carcinoma incidence post-HCV cure.
  • Patients achieving recompensation still face higher risks than those with compensated ACLD.
Abstract

Keywords:
Advanced Chronic Liver DiseaseCirrhosisHepatitis C VirusHepatocellular CarcinomaPortal Vein ThrombosisSustained Virologic Response

More Related Videos

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies07:10

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

16.2K
Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

12.0K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
179
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
248
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.2K
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
518
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
397
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
307